Xenon Pharmaceuticals Inc. has announced new data from its ongoing clinical development in epilepsy, including interim 48-month results from the X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures. According to the company, participants treated for 48 months or longer experienced a monthly reduction in seizure frequency of 90.9%, with 38% achieving at least one year of seizure freedom. The new data suggest that long-term use of azetukalner may enable patients to attain and regain extended periods of seizure freedom, including in those with difficult-to-treat disease. These results, along with multiple real-world studies on the burden of depression and anti-seizure medication titration in epilepsy, are being presented at the American Epilepsy Society Annual Meeting (AES 2025), held from December 5-9, 2025, in Atlanta, Georgia. Additionally, new pre-clinical research in Dravet syndrome was presented, indicating potential for improved motor function through Na V 1.1 potentiation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597483-en) on December 05, 2025, and is solely responsible for the information contained therein.
Comments